KalVista Pharmaceuticals (NASDAQ: KALV) received a "buy" rating from Needham & Company with a target price of $32.00.

KalVista Pharmaceuticals (NASDAQ: KALV) received a "buy" rating from Needham & Company with a target price of $32.00, following a Q3 earnings report showing an EPS of ($0.87), surpassing estimates. The company, with a market cap of $513.02 million, has seen insider selling and mixed institutional investment activities. HC Wainwright also maintains a buy rating with a $20 target, while Cantor Fitzgerald upgraded it to strong-buy.

September 10, 2024
4 Articles